Pelthos Therapeutics (PTHS) Research & Development (2023 - 2026)

Pelthos Therapeutics has reported Research & Development for 4 years, with the latest figure at $786000.0 in Q2 2026.

• On a quarterly basis, Research & Development rose 52.62% year-over-year to $786000.0 in Q2 2026; TTM through Jun 2026 was $1.5 million, a 5.82% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, up 4.16% from the prior year.
• Research & Development was $786000.0 for Q2 2026 at Pelthos Therapeutics, up from $186000.0 in the prior quarter.
• The five-year high for Research & Development was $2.3 million in Q4 2023, with the low at $12955.0 in Q2 2024.
• Average Research & Development over 4 years is $425641.4, with a median of $239500.0 recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Research & Development sank 87.58% in 2024, then surged 3875.3% in 2025.
• Over 4 years, Research & Development stood at $2.3 million in 2023, then tumbled by 87.58% to $285000.0 in 2024, then surged by 31.23% to $374000.0 in 2025, then surged by 110.16% to $786000.0 in 2026.
• The last three Research & Development figures came in at $786000.0 (Q2 2026), $186000.0 (Q1 2026), and $374000.0 (Q4 2025), per Business Quant data.